Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay

NCT ID: NCT02167113

Last Updated: 2018-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

331 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-03-31

Study Completion Date

2018-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This non-interventional clinical study will be conducted to prospectively collect serial plasma samples from subjects with chronic HBV infection who are initiating antiviral therapy. These samples will be used to estimate clinical utility endpoints for the Aptima HBV Quant assay, which is used as an aid in the management of HBV-infected patients undergoing HBV antiviral therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study population

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is chronically infected with HBV.The subject is treatment naïve and is initiating HBV antiviral therapy with either entecavir or tenofovir as indicated in the FDA approved label
* The subject will be considered treatment naïve if he/she had \<12 weeks of oral antiviral therapy with any nucleoside or nucleotide therapy
* The subject is at least 18 years of age at the time of enrollment
* Adequate medical records are available for collection of protocol-defined demographics, baseline patient characteristics, medical history, virology and specific laboratory results, and other information to verify enrollment criteria
* The subject and/or legally authorized representative is willing and able to provide consent prior to providing a specimen(s)

Exclusion Criteria

* Subject is in one of the following patient populations:

* Acute HBV infection
* Patients who are HBV immune tolerant
* Human immunodeficiency virus (HIV) and/or hepatitis C virus (HCV) co-infection
* Solid organ or bone marrow transplant recipients
* Renal failure or dialysis
* Evidence or history of hepatic decompensation
* Evidence or history of hepatocellular carcinoma
* Underlying liver disease other than HBV
* Receiving chemotherapy, immunosuppressive agents
* Subject is unsuitable for study participation based on the Investigator's decision (eg, unlikely to comply with study visit schedule, significant medical complication)
* Participating in another investigational study that the Investigator believes might interfere with the subject's participation in this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hologic, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christine Kuslich

Role: STUDY_DIRECTOR

Hologic, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner Health Good Samaritan

Phoenix, Arizona, United States

Site Status

Dignity Health - St. Joseph's Hospital

Phoenix, Arizona, United States

Site Status

Advanced Rx Clinical Research

Garden Grove, California, United States

Site Status

High Desert Gastroenterology

Lancaster, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, United States

Site Status

Stanford University Medical Center

Palo Alto, California, United States

Site Status

Inland Empire Liver Foundation

Rialto, California, United States

Site Status

Kaiser Permanente

San Diego, California, United States

Site Status

Kaiser Foundation Hospital

San Francisco, California, United States

Site Status

San Jose Gastroenterology

San Jose, California, United States

Site Status

South Bay Gastroenterology Medical Group

Torrance, California, United States

Site Status

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

Schiff Center for Liver Disease

Miami, Florida, United States

Site Status

Digestive Healthcare of Georgia

Atlanta, Georgia, United States

Site Status

Gastrointestinal Specialists of Georgia

Marietta, Georgia, United States

Site Status

Mercy Medical Center

Baltimore, Maryland, United States

Site Status

Digestive Disease Associates, PA

Catonsville, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Newton-Wellesley Hospital

Newton, Massachusetts, United States

Site Status

The Research Institute

Springfield, Massachusetts, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

University of Medicine and Dentistry of New Jersey

Newark, New Jersey, United States

Site Status

Sing Chan, MD

Flushing, New York, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status

Carolinas HealthCare System

Charlotte, North Carolina, United States

Site Status

Piedmont HealthCare

Statesville, North Carolina, United States

Site Status

Integris Baptist Medical Center

Oklahoma City, Oklahoma, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Einstein Healthcare Network

Philadelphia, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Nashville Medical Research Institute

Nashville, Tennessee, United States

Site Status

Austin Center for Clinical Research

Austin, Texas, United States

Site Status

Kelsey Research Foundation

Houston, Texas, United States

Site Status

Liver Associates of Texas

Houston, Texas, United States

Site Status

University of Utah School of Medicine

Salt Lake City, Utah, United States

Site Status

Digestive and Liver Disease Specialists

Norfolk, Virginia, United States

Site Status

Harborview Medical Center

Seattle, Washington, United States

Site Status

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Site Status

Napean Hospital, Gastroenterology and Hepatology Department

Kingswood, New South Wales, Australia

Site Status

Liverpool Hospital, Department of Gastroenterology

Sydney, New South Wales, Australia

Site Status

St Vincent's Hospital Department of Gastroenterology

Fitzroy, Victoria, Australia

Site Status

UMHAT Dr. Gerogi Stranski, Clinic of Gastroenterology

Pleven, , Bulgaria

Site Status

UMHAT Aleksandrovska, Clinic of Gastroenterology

Sofia, , Bulgaria

Site Status

UMHAT Sveti Ivan Rilski Clinic of Gastroenterology

Sofia, , Bulgaria

Site Status

Foothills Medical Centre

Calgary, Alberta, Canada

Site Status

Lair Centre

Vancouver, British Columbia, Canada

Site Status

University of British Columbia

Vancouver, British Columbia, Canada

Site Status

GI Research Institute

Vancouver, British Columbia, Canada

Site Status

London Health Sciences Centre

London, Ontario, Canada

Site Status

Toronto Liver Centre

Toronto, Ontario, Canada

Site Status

Leberzentrum am Checkpoint Fachärztegemeinschaft für innere Krankheiten

Berlin, , Germany

Site Status

Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie

Berlin, , Germany

Site Status

Zentrum für Infektiologie Berlin Prenzlauer Berg

Berlin, , Germany

Site Status

Universitätsklinikum Essen Klinik für Gastroenterologie und Hepatologie

Essen, , Germany

Site Status

ifi-Studien und Projekte GmbH An der Asklepios Klinik St. Georg, Haus L

Hamburg, , Germany

Site Status

ifi-Studien und Projekte GmbH, An der Asklepios Klinik St. Georg

Hamburg, , Germany

Site Status

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, , Germany

Site Status

Universitätsmedizin Mannheim II. Medizinische Klinik

Mannheim, , Germany

Site Status

Szent István és Szent László Kórház

Budapest, , Hungary

Site Status

Budai Hepatollógiai Központ

Budapest, , Hungary

Site Status

Szent János Kórház

Budapest, , Hungary

Site Status

Budai Hepatollógiai Központ

Budapest, , Hungary

Site Status

Szent János Kórház

Budapest, , Hungary

Site Status

Pándy Kálmán Megyei Kórház

Gyula, , Hungary

Site Status

'Ospdale Da Procida

Salerno, , Italy

Site Status

'Medicina Interna - Ospedale Civile

Sassari, , Italy

Site Status

Medicina Interna - Ospedale Civile

Sassari, , Italy

Site Status

Auckland Liver Research Unit

Grafton, Auckland, New Zealand

Site Status

Waikato Gastroenterology and Respiratory Research Office

Hamilton West, Waikato Region, New Zealand

Site Status

Gastroenterology Research, Wellington Hospital

Newton, Wellington Region, New Zealand

Site Status

Spitalul Universitar de Urgenta Militar Central "Dr. Carol Davila"

Sector 1, București, Romania

Site Status

Institutul de Boli Infectioase "Prof. Dr. Matei Bals"

Sector 2, București, Romania

Site Status

Institutul Clinic Fundeni, Bucuresti

Sector 2, București, Romania

Site Status

Spitalul Universitar de Urgenta Bucuresti

Sector 5, București, Romania

Site Status

Spitalul Clininc de Boli Infecţioase Constanţa

Constanța, Constanța County, Romania

Site Status

Spitalul Clinic Judetean de Urgenta Sibiu

Sibiu, Jud. Sibiu, Romania

Site Status

Policlinica Algomed, Timisoara

Timișoara, Jud. Timis, Romania

Site Status

Istanbul University Cerrahpaşa School of Medicine

Istanbul, Istanbul, Turkey (Türkiye)

Site Status

Ankara University School of Medicine

Ankara, , Turkey (Türkiye)

Site Status

Yıldırım Beyazıt University Atatürk Training and Research Hospital

Ankara, , Turkey (Türkiye)

Site Status

Adnan Menderes Üniversitesi

Aydin, , Turkey (Türkiye)

Site Status

Uludag University School of Medicine

Bursa, , Turkey (Türkiye)

Site Status

Dicle University School of Medicine

Diyarbakır, , Turkey (Türkiye)

Site Status

Osmangazi University School of Medicine

Eskişehir, , Turkey (Türkiye)

Site Status

Istanbul University Istanbul School of Medicine

Istanbul, , Turkey (Türkiye)

Site Status

Dokuz Eylül University School of Medicine

Izmir, , Turkey (Türkiye)

Site Status

Kocaeli University School of Medicine

Kocaeli, , Turkey (Türkiye)

Site Status

Selçuk University School of Medicine

Konya, , Turkey (Türkiye)

Site Status

Ondokuz Mayıs University School of Medicine

Samsun, , Turkey (Türkiye)

Site Status

Karadeniz Technical University School of Medicine

Trabzon, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Bulgaria Canada Germany Hungary Italy New Zealand Romania Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

V10434-HBVQPS-CSP-01

Identifier Type: OTHER

Identifier Source: secondary_id

V10434-HBVQPS-CSP-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.